Cross-reaction with luteinizing hormone [beta]-core is responsible for the age-dependent increase of immunoreactive [beta]-core fragment of human chorionic gonadotropin in women with nonmalignant conditions.
hCG[beta]cf/[beta]-core is a major immunoreactive degradation product of hCG and its free [beta]-subunit and is often the only form of hCG present in the urine of cancer patients (8, 9). The process by which hCG[beta]cf/[beta]-core arises starts in the circulation with cleavage or "nicking" of amide bonds between residues 47 and 48 and, less frequently, between residues 42 and 43 of hCG[beta], either as part of the intact heterodimer or as a free subunit (10, 11). This nicking occurs at the center of a major hCG/luteinizing hormone (LH) receptor binding loop (12,13). These nicked molecules are then taken up by the kidneys and further degraded to hCG[beta]cf/[beta]-core, which is excreted into the urine (14). Although missing 53 amino acids of the COON terminus, 5 amino acids of the N[H.sub.2] terminus, and residues 41-54, hCG[beta]cf/[beta]-core retains many antigenic epitopes of its parent molecule because it retains a core, or central knot, of three sets of disulfide bond pairs, which are responsible for much of the three-dimensional shape of hCG[beta] (8).
Increased urinary hCG[beta]cf/[beta]-core was proposed originally as a general marker of gynecological cancer (vaginal, cervical, ovarian, and endometrial) (15-17). However, immunoreactive "[beta]-core" is detectable in urine of women with no malignant disease. Indeed, there is a general increase with age, especially after menopause (18). Thus, cutoff values between normal and abnormal must be adjusted according to menopausal status. Subsequent studies demonstrated that much of this immunoreactive [beta]-core could be attributed to cross-reaction with a metabolite of LH, which we termed [beta]-LH-core and which was almost certainly produced by the same degradation pathways that led to hCG[beta]cf (19). Nevertheless, using a highly specific assay, Alfthan et al. (20) suggested that there was still an underlying increase in hCG[beta]cf with age. Recently, [beta]-LH-core was purified by Birken et al. (21) at Columbia University, New York. We have assessed the molar crossreactivity of [beta]-LH-core in our in-house [beta]-core, hCG, LH, free [alpha]-subunit, and free hCG[beta] assays along with a recently developed [beta]-core assay, Triton UGP, which includes a pretreatment LH "scavenger" antibody step to remove cross-reacting LH metabolites.
We used these assays to measure immunoreactive [beta]-core in 254 women with nonmalignant conditions to determine whether the detected hCG[beta]cf could be accounted for by cross-reactivity with [beta]-LH-core.
Materials and Methods
Urine samples were collected from 254 women attending St. Bartholomew's Hospital with nonmalignant pathology. Samples were stored frozen at -20[degrees]C until assay. The creatinine concentration of each sample was measured by the Jaffe method on a Monarch 200 centrifugal analyzer.
Intact hCG was measured with an in-house IRMA with a polyclonal anti-[alpha]-subunit capture antibody conjugated to l,l'-carbonyldiimidazole (CDI)-activated cellulose and a [sup.125]I-radiolabeled monoclonal antibody 1/07 (Quantum Bioscience) to epitopes on the hCG[beta] C-terminal peptide. The calibration curve ranged from 2.6 to 813 pmol/L.
LH was measured using an LH IRMA produced by North East Thames Immunoassay, St. Bartholomew's Hospital. This uses a polyclonal anti-LH antiserum for capture onto a CDI-activated cellulose solid phase and the same antibody, affinity purified and [sup.125]I-radiolabeled, for detection. The calibration curve ranged from 34 to 1333 pmol/L.
Free [alpha]-subunit was measured by use of an in-house RIA with an antiserum (S781) raised against the free [alpha]-subunit and affinity absorbed on a column of intact hCG conjugated to CNBr-activated Sepharose. The tracer was [sup.125]I-radiolabeled purified free [alpha]-subunit (NIH preparation CR123 [alpha]-subunit). The calibration curve ranged from 62.5 to 6250 pmol/L.
Free hCG[beta] was measured using an in-house IRMA. A polyclonal antiserum (5752) raised in sheep against free hCG[beta] was conjugated to CDI-activated cellulose. Free hCG[beta] captured onto this solid phase was detected by [sup.125]I-radiolabeled monoclonal antibody 1/07, which recognizes epitopes on the hCG[beta] C-terminal peptide. A calibration curve was constructed by plotting bound [gamma]-activity values against increasing concentration of hCG[beta] (NIH preparation CR123). The cross-reactivity of this assay is detailed the Results, the calibration curve ranged from 22 to 1110 pmol/L.
[FIGURE 1 OMITTED]
The in-house [beta]-core RIA used a polyclonal antibody to hCG[beta]cf (S504) in a late addition competition assay using [sup.125]I-radiolabeled purified hCG[beta]cf (18). This assay is known to cross-react with [beta]-LH-core (19). The calibration curve ranged from 9 to 500 pmol/L.
The commercial Triton ELISA uses a scavenger anti-LH antibody in the initial diluent to bind LH-like material. The assay used an immobilized monoclonal antibody against hCG[beta]cf and a peroxidase-conjugated polyclonal antibody to hCG[beta] (and thus epitopes retained by hCG[beta]cf). The calibration curve ranged from 2 to 16 pmol/L.
Hormones and subunits were NIH preparations (CR123) of intact hCG, free hCG[beta], and [alpha]-subunit of hCG; WHO International Reference Preparations of LH (LH-68/40), follicle-stimulating hormone (FSH; FSH-83/575), and thyrotropin (TSH; TSH-80/558; National Institute for Biological Calibrations and Control, Potters Bar, Herts, UK). Purified hCG[beta]cf was donated by Drs. R. Wehmann and D. Blithe (NIH, Bethesda, MD). Recently purified [beta]-LH-core was kindly donated by Dr. S. Birken (Presbyterian Medical Center, Irving Center for Clinical Research, Columbia University, New York, NY). Cross-reactivity was determined on a molar basis using molecular weights calculated from the established primary structures: intact hCG, [M.sub.r] 36 700; free hCG[beta], MT 22 200; free [alpha]-subunit, [M.sub.r] 14 500 (22, 23); hCG[beta]cf and [beta]-LH-core, [M.sub.r] 10 000 (21, 24); LH, [M.sub.r] 29 000; FSH, [M.sub.r] 33 000; and TSH, [M.sub.r] 30 000 (19).
Cross-reactivities were calculated from the molar equivalents that produce 50% B/[B.sub.o] displacement for the RIA and at concentrations in the IRMA and enzyme immunoassay at which calibrator and cross-reactant curves paralleled.
Matched assay results for the samples were examined for correlations using the Spearman rank test (adjusted for ties). Calculations were performed using Astute (statistics add-in for Microsoft Excel; DDU software, University of Leeds, UK).
The cross-reactivities of each assay are shown in Table 1. Significantly, [beta]-LH-core yielded a 100% cross-reactivity with the LH IRMA and with the [beta]-core (S504) RIA. The Triton UGP [beta]-core assay showed a 5% cross-reaction with [beta]-LH-core (Fig. 1).
[FIGURE 2 OMITTED]
Age-dependent increases were seen (Fig. 2) in the median values of apparent immunoreactive LH, hCG, free hCG[beta], free [alpha]-subunit, S504 RIA [beta]-core, and Triton UGP [beta]-core.
LH and free [alpha]-subunit concentrations were ~[10.sup.3] pmol/mol creatinine, hCG and S504 [beta]-core concentrations were ~[10.sup.2] pmol/mol creatinine, and free hCG[beta] and Triton UGP [beta]-core concentrations were ~10 pmol/mol creatinine (Table 2).
A correlation analysis between [beta]-core concentrations and all other hCG, LH, and free subunits analytes was conducted (Table 3 and Fig. 3). The S504 [beta]-core concentrations were 10% of those of LH, and there was a stronger correlation of S504 [beta]-core concentrations with LH than with hCG or free hCG[beta] within individual sample (LH, [r.sup.2] = 0.45; hCG, [r.sup.2] = 0.26; free hCG[beta], [r.sup.2] = 0.03; P = 0.60). The concentrations of [beta]-core detected by the Triton UGP assay were 2% of the LH and 5% of the S504 [beta]-core concentrations. Triton UGP [beta]-core values similarly correlated more strongly with LH and S504 [beta]-core concentrations than with intact hCG and free hCG[beta] (LH, [r.sup.2] = 0.44; S504 [beta]-core, [r.sup.2] = 0.33; hCG, [r.sup.2] = 0.32; free hCG[beta], [r.sup.2] = 0.19).
The use of [beta]-core as a tumor marker is complicated by reports of variable urine concentration (2), changes during the menstrual cycle (25), and higher excretion in the postmenopausal age groups (18, 26). Our results suggest that cross-reacting [beta]-LH-core was responsible for the age-related increase in basal [beta]-core concentrations (19). The proposed [beta]-LH-core molecule, arising from the same metabolic processes, would share an 82% amino acid sequence homology, and the conserved cysteine knot disulfide would render the two molecules topologically identical. Assay systems developed to distinguish intact hCG and free hCG[beta] from hCG[beta]cf would, by definition, be directed to regions that are unique to the degraded core molecule. Because the same degradation process is likely to act on both hCG[beta] and LH[beta] (and most probably FSH[beta] and TSH[beta]) the resulting core-defining epitopes would be common to all glycoprotein hormone urinary [beta]-core molecules (19, 27). For this reason, the Triton UGP ELISA for hCG[beta]cf incorporates a scavenger antibody for LH-like material.
[FIGURE 3 OMITTED]
Purified [beta]-LH-core did not cross-react in the free hCG[beta], free [alpha]-subunit, and intact hCG assays, but showed 100% cross-reaction in the LH and S-504 [beta]-core assays. However, [beta]-LH-core showed 5% cross-reaction in the Triton UGP [beta]-core, despite pretreatment of samples with the LH scavenger antibody (Fig. 1).
On a molar basis, immunoreactive LH was the most abundant form of gonadotropic molecule in the urine of pre- and postmenopausal women. Both LH and free [alpha]-subunit concentrations were in the ~[10.sup.3] pmol/mol creatinine range; S504 RIA [beta]-core was in the ~[10.sup.2] pmol/ mol creatinine range; free hCG[beta] and intact hCG were in the ~10 pmol/mol creatinine range; and Triton UGP [beta]-core was in the ~1 pmol/mol creatinine range. Thus, cross-reactivity with LH and LH-related [beta]-LH-core is highly likely to influence the immunochemical measurement of other related gonadotropic peptides. For example, an hCG assay with 0.1% cross-reactivity with LH would measure apparent hCG concentrations in the urine of women >60 years of age as 2.7 pmol/mol creatinine, simply because of cross-reactivity.
Given the data on specificity for the various assays used in this study, all the apparent [beta]-core measured by the S504 RIA in these samples could be accounted for by cross-reaction with [beta]-LH-core. This interpretation is supported by the fact that there was a strong correlation between the S504 RIA concentrations of [beta]-core and LH concentrations ([r.sup.2] = 0.45), but not with hCG and hCG[beta] concentrations ([r.sup.2] = 0.26 and 0.03, respectively). Thus, [beta]-LH-core could represent 10% of the LH immunoreactivity of the samples measured using the LH IRMA (this IRMA cross-reacts 100% with [beta]-LH-core). The concentrations of [beta]-core detected by the Triton UGP assay were 5% of those detected by the S504 [beta]-core RIA and 2% of the LH concentrations. Given that the UGP assay has a 5% cross-reactivity with authentic [beta]-LH-core, this is consistent with all of the [beta]-core immunoreactivity found in the samples being attributable to cross-reaction with [beta]-LH-core.
Alfthan et al. (20) claimed a true increase in urinary hCG[beta]cf with age. However, there were no data on the cross-reactivity of authentic [beta]-LH-core in their assay system. The median concentration of immunoreactive [beta]-core found in urine by Alfthan et al. was 70 pmol/mol creatinine for those <50 years of age and 230 pmol/mol creatinine for those >50 years of age. This is consistent with the concentrations (molar ratios) detected by the S504 [beta]-core RIA. Furthermore, their studies of male urinary hCG[beta]cf showed no dramatic increase with age. Thus, we believe it is possible that the assay developed by Alfthan et al. also cross-reacts 100% with [beta]-LH-core.
Free intact hCG and free hCG[beta] concentrations also rose with age. However, hCG and free hCG[beta] concentrations did not correlate significantly with hCG[beta]cf (see Table 3) and reactivity of LH and [beta]-LH-core in these assays was <0.1%. Intact hCG and free hCG[beta] showed a weak correlation ([r.sup.2] = 0.37), and hCG[beta] concentrations were approximately 20% of those of intact hCG. The origin of these true hCG species is unknown, although hCG and free hCG[beta] expression has been demonstrated in the nonmalignant pituitary (28,29) and in testicular (30), prostatic (31), and urothelial epidermal tissues (32).
In conclusion, most, if not all, [beta]-core immunoreactivity found in the urine of healthy pre- and postmenopausal women and patients with nonmalignant gynecological conditions can be attributed to cross-reaction of the assays with the urinary metabolite of LH, [beta]-LH-core. Any true hCG[beta]cf, derived from extremely low-level expression of the hCG[beta] gene cluster by pituitary gonadotrophs, is likely to be extremely low and much smaller than immunoreactivity from cross-reacting [beta]-LH-core metabolite. If assays can be developed that clearly distinguish between urinary [beta]-LH-core and hCG[beta]cf, the issue of the clinical utility of hCG[beta]cf as a tumor marker should be reexamined.
We thank Dr. Steve Birken for pure LH[beta]cf. This study was supported by grants from the Cancer Research Committee and Joint Research Board of St. Bartholomew's Hospital, London, UK.
(1.) Cole LA, Wang Y, Ellio, M, Latif M, Chambers JT, Chambers SK, Schwartz PE. Urinary human chorionic gonadotrophin free [beta]-subunit and core fragment: a new marker of gynecological cancers. Cancer Res 1988;48:1356-60.
(2.) Carter PG, Iles RK, Neven P, Ind TEJ, Shepherd JH, Chard T. Measurement of urinary [beta] core fragment of human chorionic gonadotrophin in women with vulvovaginal malignancy and its prognostic significance. Br J Cancer 1995;71:350-3.
(3.) Carter PG, Iles RK, Neven P, Ind TEJ, Shepherd JH, Chard T. The prognostic significance of urinary [beta] core fragment in premenopausal women with carcinoma of the cervix. Gynecol Oncol 1994; 55:271-6.
(4.) Iles RK, Lee CL, Oliver RTD, Chard T. Composition of intact hormone and free subunits in the hCG-like material found in serum and urine of patients with carcinoma of the bladder. Clin Endocrinol 1990;32:355-64.
(5.) Wehmann RE, Nisula BC. Metabolic and renal clearance rates of purified human chorionic gonadotropin. J Clin Investig 1981;38: 184-94.
(6.) Blithe DL, Nisula BC. Similarity of the clearance rates of free [alpha]-subunit and [alpha]-subunit dissociated from intact human chorionic gonadotropin, despite differences in sialic acid contents. Endocrinology 1987;121:1215-20.
(7.) Rosa C, Amr S, Birken S, Wehmann RE, Nisula B. Effect of desialylation of human chorionic gonadotropin on its metabolic clearance rates in humans. J Clin Endocrinol Metab 1984;59: 1215-9.
(8.) Wehmann RE, Nisula BC. Characterization of a discrete degradation product of human chorionic gonadotropin [beta]-subunit in humans. J Clin Endocrinol Metab 1980;51:101-5.
(9.) Masure HR, Jaffee WL, Sickel MA, Birken S, Canfield RE, Vaitukaitis JL. Characterization of a small molecular size urinary immunoreactive human chorionic gonadotropin (hCG) like substance produced by the placenta and hCG-secreting neoplasms. J Clin Endocrinol Metab 1981;53:1014-20.
(10.) Sakakibara R, Miyazaki S, Ishiguro M. A nicked [beta]-subunit of human chorionic gonadotropin purified from pregnancy urine. J Biol Chem 1990;107:858-62.
(11.) Cole LA, Kardana A, Parks S-Y, Braunstein GD. The deactivation of hCG by nicking and dissociation. J Clin Endocrinol Metab 1993; 76:704-10.
(12.) Ryan RJ, Keutmann HT, Charlesworth MC, McCormick DJ, Milius RP, Calvo FO, Vutyavanich HT. Structure-function relationships of gonadotrophins. Recent Prog Horm Res 1987;43:383-429.
(13.) Cole LA, Kardana A. The biological and clinical significance of nicks in human chorionic gonadotropin and its free 0-subunit. Yale J Biol Med 1991;64:573-82.
(14.) Markkanen SO, Rajaniemi HJ. Uptake and subcellular catabolism of human choriogonadotropin in the proximal tubule cells of rat kidney. Mol Cell Endocrinol 1979;104:1540-7.
(15.) Nam JH, Cole LA, Chambers JT, Schwartz PE. Urinary gonadotropin fragment, a new tumor marker. I. Assay development and cancer-specificity. Gynecol Oncol 1990;36:383-90.
(16.) Norman RJ, Buck RH, Aktar B, Mayat N, Moodley J. Detection of a small molecular species of human chorionic gonadotropin in the urine of patients with carcinoma of the cervix and cervical intra epithelial neoplasia: comparison with other assays for human chorionic gonadotropin and its fragments. Gynecol Oncol 1990; 37:254-9.
(17.) Cole LA, Tanaka A, Kim GS, Park S-Y, Koh MW, Schwartz PE, et al. Beta core fragment ([beta]-core/UGF/UGP) a tumor marker: a 7-year report. Gynecol Oncol 1996;60:264-70.
(18.) Lee CL, Iles RK, Shepherd JH, Hudson CN, Chard T. The purification and development of a radioimmunoassay fore [beta]-core fragment of human chorionic gonadotrophin in urine: application as a marker of gynaecological cancers in premenopausal and postmenopausal women. J Endocrinol 1991;130:481-9.
(19.) Iles RK, Lee CL, Howes I, Davies S, Edwards R, Chard T. Immunoreactive-core-like material in normal post menopausal urine. hCG or LH origin? Evidence for the existence of LH-core. J Endocrinol 1992;133:459-66.
(20.) Alfthan H, Haglund C, Dabek J, Stenman U. Concentrations of human choriogonadotropin, its [beta]-subunit, and the core fragment of the [beta]-subunit in serum and urine of men and nonpregnant women. Clin Chem 1992;38:1981-7.
(21.) Birken S, Chen Y, Gawinowicz MA, Agosto GM, Canfield RE, Hartree AS. Structure and significance of human luteinizing hormone-[beta]-core fragment purified from human pituitary extracts. Endocrinology 1993;133:985-9.
(22.) Bellisario R, Carlsen RB, Bahl OP. hCG linear amino acid sequence of the [alpha]-subunit. J Biol Chem 1973;248:6796-809.
(23.) Bahl OP, Carlsen RB, Bellisario R, Swaminathan N. Human chorionic gonadotropin: amino acid sequence of the alpha and beta subunits. Biochem Biophys Res Commun 1972;48:416-22.
(24.) Birken S, Armstrong EG, Gawinowicz Kolks MA, Cole LA, Agosto GM, Krichevsky A, et al. Structure of the human chorionic gonadotropin [beta]-subunit fragment from pregnancy urine. Endocrinology 1988;123:572-83.
(25.) Neven P, Iles RK, Howes I, Sharma K, Shepherd JH, Edwards R, et al. Urinary concentration of material resembling [beta]-core fragment of chorionic-gonadotropin [beta]-subunit in mid-menstrual cycle. Clin Chem 1993;39:1857-60.
(26.) Akar AH, Gervasi G, BlackerC, Wehmann RE, Blithe DL, Nisula BC. Human chorionic gonadotrophin-like and 0-core-like materials in postmenopausal urine. J Endocrinol 1990;125:477-84.
(27.) Berger P, Bidart JM, Delves PS, Dirnhofer S, Hoermann R, Isaacs N, et al. Immunological mapping of gonadotropins. Mol Cell Endocrinol 1996;125:33-43.
(28.) Hoermann R, Spoettl G, Moncayo R, Mann K. Evidence for the presence of human chorionic gonadotropin (hCG) and free [beta]-subunit of hCG in the human pituitary. J Clin Endocrinol Metab 1990;71:179-86.
(29.) Dirnhofer P, Hermann M, Hittmair A, Hoermann R, Kapelari K, Berger P. Expression of the human chorionic gonadotropin-[beta] gene cluster in human pituitaries and alternative use of exon 1. J Clin Endocrinol Metab 1996;81:4212-7.
(30.) Berger P, Kranewitter W, Madersbacher S, Gerth R, Geley S, Dirnhofer S. Eutopic production of human chorionic gonadotropin-[beta] (hCG[beta]) and luteinizing hormone-[beta] (hLH[beta]) in the human testis. FEBS Lett 1994;343:229-33.
(31.) Dirnhofer S, Koessler P, Ensinger C, Feichtinger H, Madersbacher S, Berger P. Production of trophoblastic hormones by transitional cell carcinoma of the bladder: association to tumour stage and grade. Hum Pathol 1999, in press.
(32.) Iles RK, Purkis PE, Whitchead PC, Oliver RTD, Leigh I, Chard T. Expression of R human chorionic gonadotrophin by non-trophoblastic nonendocrine 'normal' and malignant epithelial cells. Br J Cancer 1990;61:663-6.
(33.) Lapthorn AJ, Harris DC, Littlejohn A, Lustbader JW, Canfield RE, Machin KJ, et al. Crystal structure of human chorionic gonadotrophin. Nature 1994;369:455-61.
 Nonstandard abbreviations: hCG[beta], free [beta]-subunit of human chorionic gonadotropin; hCG[beta]cf, [beta]-core fragment of human chorionic gonadotropin; UGP, urinary gonadotropin peptide; MCR, metabolic clearance rate; LH, luteinizing hormone; [beta]-LH-core, [beta]-core fragment of luteinizing hormone; CDI, l,l'-carbonyldiimidazole; FSH, follicle-stimulating hormone; and TSH, thyrotropin.
RAY K. ILES, * MOHAMMED K., DAVID, LIONEL K. GUNN, and TIM CHARD
Williamson Laboratory, Department of Obstetrics and Gynecology, St. Bartholomew's and The Royal London School of Medicine and Dentistry, St. Bartholomew's Hospital, London EC1A 7BE, UK.
* Author for correspondence. Fax 44 0171-600-1439; e-mail R.K.lles@mds. gmw.ac.uk.
Received August 26, 1998; accepted January 21, 1999.
Table 1. Molar cross-reaction of the glycoprotein hormones and their related fragments in the hormone- and subunit/ fragment-specific assays used. Cross-reacting antigen Assay LH FSH TSH hCG hCG[beta] Intact hCG IRMA <0.1 <0.1 <0.1 100 <0.1 LH IRMA 100 10 10 60 20 Free hCG[beta] IRMA <0.1 <0.1 <0.1 <0.1 100 Free common [alpha]-subunit RIA 10 8 6 10 <0.1 S504 [beta]-core RIA 0.7 <0.1 <0.1 7 18 UGP [beta]-core ELISA <0.1 <0.1 <0.1 <0.1 <0.1 Cross-reacting antigen Common [beta]-LH-core Assay [alpha]-subunit hCG[beta]cf LH[beta]cf) Intact hCG IRMA <0.1 <0.1 <0.1 LH IRMA 7 <0.1 100 Free hCG[beta] IRMA <0.1 <0.1 <0.1 Free common [alpha]-subunit RIA <0.1 <0.1 <0.1 S504 [beta]-core RIA <0.1 100 100 UGP [beta]-core ELISA <0.1 100 5 Table 2. Immunoreactive concentrations (a) (pmol-mol creatinine) of hCG, LH, free hCG[beta] subunit, free [alpha]-subunit, and [beta]-core in the urine of women 20 to Age group >80 years of age with benign gynecological conditions. Age group 20-29 30-39 40-49 n 18 35 28 Free a-subunit 450 550 931 (ND to 1300) (b) (ND to 2232) (ND to 2663) Free hCG[beta] ND ND 8.88 (ND to 39.96) (ND to 84.36) (ND to 84.36) hCG ND ND ND (ND to ND) (ND to 139.39) (ND to 202.51) LH 1349 1846 2084 (593-2491) (1314-4720) (1297-3012) S504 [beta]-core ND 60 230 (ND to 170) (ND to 330) (ND to 410) UGP [beta]-core ND ND ND (ND to ND) (ND to ND) (ND to ND) Age group 50-59 60-69 n 26 46 Free a-subunit 1793 2294 (725-3794) (1131-3419) Free hCG[beta] 8.88 22.2 (ND to 53.28) (ND to 44.4) hCG 38.66 142.02 (ND to 291.93) (ND to 357.68) LH 2011 2698 (1211-3726) (1659-6062) S504 [beta]-core 300 310 (ND to 570) (80-460) UGP [beta]-core ND 4 (ND to 1) (ND to 26) Age group 70-79 ?80 n 46 55 Free a-subunit 2600 2900 (925-3894) (1219-4606) Free hCG[beta] 22.2 48.84 (ND to 57.72) (ND to 111) hCG 126.24 152.54 (ND to 318.23) (ND to 268.26) LH 4023 4213 (2922-5596) (2232-6200) S504 [beta]-core 250 300 (ND to 450) (ND to 640) UGP [beta]-core 15 11 (ND to 37) (ND to 36) (a) Values given as median (interquartile range). (b) ND, not detected. Table 3. Correlation statistics (a) of hCG and related metabolites. hCG[beta] hCG LH Common 0.25 0.41 0.68 [alpha]-subunit (P = 0.0001) (P <0.0001) (P <0.0001) hCG(3 0.37 0.19 (P <0.0001) (P = 0.0049) hCG 0.49 (P <0.0001) LH S504 0-core RIA hCGRcf S504 [beta] -core RIA UGP ELISA hCG/3cf hCG/3cf Common 0.43 0.38 [alpha]-subunit (P <0.0001) (P <0.0001) hCG(3 0.03 0.19 (P = 0.60) (P = 0.004) hCG 0.26 0.32 (P <0.0001) (P <0.0001) LH 0.45 0.44 (P <0.0001) (P <0.0001) S504 0-core 0.33 RIA hCGRcf (P <0.0001) (a) Values are Spearman rank correlations ([r.sup.2]) values between analyze concentrations in 224 samples (corrected for ties). Probability is shown in parentheses.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Endocrinology and Metabolism|
|Author:||Iles, Ray K.; Javid, Mohammed K.; Gunn, Lionel K.; Chard, Tim|
|Date:||Apr 1, 1999|
|Previous Article:||Immunoradiometric assay for intact human osteocalcin(I-49) without cross-reactivity to breakdown products.|
|Next Article:||[sup.1]H-NMR spectroscopy of body fluids: inborn errors of purine and pyrimidine metabolism.|